Pharma Focus America

Secarna Pharmaceuticals and Orbit Discovery Join Forces to Explore Peptide-Conjugated Targeted Antisense Oligonucleotide Therapeutics

Wednesday, May 29, 2024

Secarna Pharmaceuticals GmbH & Co. KG (Secarna) and Orbit Discovery Ltd. (Orbit) have entered into a significant collaboration to advance targeted therapeutics. They aim to develop peptide-conjugated antisense oligonucleotide (ASO) drugs. By combining Orbit's expertise in therapeutic peptide discovery with Secarna's ASO development capabilities, the collaboration seeks to expand the therapeutic potential of ASO molecules beyond traditional modalities like antibodies and GalNAc sugar molecules.

Konstantin Petropoulos, Secarna's Chief Business Officer, expressed excitement about the partnership, highlighting Orbit's contributions as a significant asset. By integrating Orbit's bead-based peptide display engine into Secarna's ASO platform, they aim to develop highly specific, potent, and safe therapeutic options for patients across various diseases.

Orbit's technology allows for rapid screening of extensive peptide libraries, both in solution and within cells, facilitating the identification of promising leads. Dr. Neil Butt, CEO of Orbit Discovery, underscored the collaboration's importance in meeting the growing demand for targeted therapeutics. He emphasized the potential of their joint efforts to revolutionize treatment options globally, making them safer and more effective.

In summary, this collaboration strengthens Secarna's position in targeted ASO therapeutics and promises to extend the reach of antisense approaches, potentially transforming treatment options for a wide range of diseases.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024